Here is what you need to know on Monday, February 22:
Markets are on the back foot amid concerns of a quick return to growth, reflating or even inflating prices, with bond yields, oil and copper on the rise, but the dollar falling. The UK's roadmap of returning to normal, the German IFO Business Climate and news related to US fiscal stimulus are eyed.
Reflation trade: Investors are awaiting what President Joe Biden and fellow Democrats pass in Congress – up to $1.9 trillion in covid relief – and what they might do afterward. The administration is considering vast infrastructure spending. Prospects of high debt issuance have caused a sell-off in bonds, but the higher yields have yet to boost the dollar.
Commodities "supercycle:" China's 2020 growth and prospects of a US rebound have boosted oil prices after a short profit-taking move. It is unclear how Saudi Arabia and Russia will manage output cuts moving forward. Copper has surged past $9,000 amid supply issues on top of expectations for robust global growth.
Bitcoin hit a new high above $58,000, surpassing a valuation of $1 trillion at one point. Ethereum is trading near its record of over $2,000. Tesla's founder Elon Musk touted Dogecoin once again.
Jerome Powell, Chairman of the Federal Reserve, is scheduled to testify before Congress on Tuesday and on Wednesday, yet his prepared remarks may come out as early as Monday. The central banker's comments on inflation, employment and other topics will be closely watched.
UK: GBP/USD is holding onto 1.40 it reached late last week and ahead of a highly anticipated speech by Prime Minister Boris Johnson on easing restrictions. According to reports, he is set to lay out a cautious roadmap to reopening and stress the importance of vaccinations.
Europe: The German IFO Business Climate figures for February are set to show an improvement in sentiment, echoing similar figures from ZEW. EUR/USD has been hovering above 1.21.
Vaccines: Another study in Israel has shown that the Pfizer/BioNTech jabs have dramatically reduced infection and not only disease. The country of nine million has already reached 47% of its population with at least one shot. The US FDA is scheduled to discuss Johnson and Johnson's single-shot vaccine on Friday.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.